China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab (SCT400), marking the official national launch of the drug in China. The innovative CD20 monoclonal antibody (mAb) is described as similar in efficacy and safety to rituximab and was approved on August 31 for treating newly diagnosed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL).
Usage and Clinical Data
Ripertamab is indicated for use in combination with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for adult patients with newly diagnosed CD20-positive DLBCL with an International Prognostic Index (IPI) score of 0 to 2. Phase III clinical data demonstrated that ripertamab achieved a significant curative effect and was not inferior to rituximab. The drug’s safety profile was comparable to rituximab, with a notable reduction in the incidence of interstitial lung disease and pulmonary inflammation adverse reactions.-Fineline Info & Tech
